Overview
Research indicates a correlation between the use of estrogen-only hormone therapy and a reduced incidence of dementia and fewer neuropathological markers associated with Alzheimer's disease in women. This observation stems from an extensive study involving over 21,000 participants.
Research Context
The investigation focused on women who underwent estrogen-only hormone therapy during their later life stages. The primary objective was to assess its association with neurological outcomes, specifically dementia diagnosis and the presence of Alzheimer's-related brain alterations.
Approach
This large-scale study analyzed data from more than 21,000 participants. The methodology involved evaluating the relationship between reported estrogen-only hormone therapy use and subsequent medical diagnoses, along with post-mortem pathological findings. Specifically, it assessed dementia diagnoses and Alzheimer’s-related brain changes observed at autopsy. Additionally, biomarker tests were employed to ascertain levels of amyloid buildup.
Findings
- Women who utilized estrogen-only hormone therapy exhibited a 39% reduction in the odds of receiving a dementia diagnosis.
- Analysis of autopsy data revealed that these hormone therapy users were 35% less likely to display Alzheimer’s-related brain changes. These changes encompassed the presence of amyloid plaques and tau tangles.
- Biomarker tests further suggested a lower accumulation of amyloid among individuals who had used hormone therapy.
Why This Matters
The findings from this large study suggest that estrogen-only hormone therapy administered later in life may be associated with protective effects against dementia and the neuropathological hallmarks of Alzheimer's disease.